

**ALBERTA SECURITIES COMMISSION**

**REVOCATION ORDER**  
**Under the *Securities Act (Alberta) (the Act)***

**Citation: Re Hillestad Pharmaceuticals Inc., 2021 ABASC 1**

**Date: 20210107**

**Hillestad Pharmaceuticals Inc.**

**Background**

1. Hillestad Pharmaceuticals Inc. (the **Issuer**) is subject to a cease trade order (the **CTO**) issued by the Executive Director of the Alberta Securities Commission on 1 February 2007, *Re Hillestad Pharmaceuticals Inc.* 2007 ABASC 59.
2. The Issuer has applied for an order under section 214 of the Act revoking the CTO.

**Interpretation**

3. Terms defined in National Instrument 14-101 *Definitions* have the same meaning if used in this order, unless otherwise defined.

**Representations**

4. This order is based on the following facts represented by the Issuer:
  - (a) It is a reporting issuer under the Act.
  - (b) It has filed with the Executive Director all continuous disclosure that it is required to file under the Alberta securities laws, except any continuous disclosure that the Executive Director elected not to require as contemplated in sections 6 and 7 of National Policy 12-202 *Revocation of Certain Cease Trade Orders*, and has paid all activity, participation and late filing fees that it is required to pay to the Alberta Securities Commission.
  - (c) It has an up-to-date SEDAR profile and SEDI issuer profile supplement.

**Decision**

5. The undersigned, considering that it would not be prejudicial to the public interest to do so, orders under subsection 214(1.1) of the Act that the CTO is revoked.

7 January 2021

*“original signed by”*

Timothy Robson  
Manager, Legal  
Corporate Finance  
Alberta Securities Commission